Latest Turner Pope Aptamer note31 Mar 2026 16:01
hide quoted text
---------- forwarded message ---------
from: fred his**** <fhjhis****@gmail.com>
date: tue, 31 mar 2026, 15:56
subject: fwd: aptamer group plc (apta) research note - 31.03.2026
to: fred his**** <fhjhis****@gmail.com>
---------- forwarded message ---------
from: fred his**** <fhjhis****@gmail.com>
date: tue, 31 mar 2026, 15:51
subject: fwd: aptamer group plc (apta) research note - 31.03.2026
to: <fhjhis****@gmail.com>
---------- forwarded message ---------
from: turner pope investments (tpi) limited <info@turnerpope.com>
date: tue, 31 mar 2026, 13:01
subject: aptamer group plc (apta) research note - 31.03.2026
to: <fhjhis****@gmail.com>
view this email in your browser
aptamer group plc (apta)
tpi is pleased to provide its latest research note on aptamer group plc (apta.l).
aptamer has raised a total of £4.50m (gross) new funding pursuant to a £4.275m accelerated book build (‘the abb’), comprising a placing (the ‘placing’) and subscription (the ‘subscription’) to new and existing shareholders at 0.6p/share (representing a 7.7% discount to tuesday, 26 march’s closing price), followed by a retail offer (‘the retail offer’) that contributed a further £0.274m on the same terms. the abb was split into firm and conditional allocations, the latter of which will, along with the subscription and retail offer (altogether totalling c.£3.1m), be subject to shareholder approval at a general meeting scheduled for 13 april 2026. participants in the fundraise will also receive one warrant to subscribe for one new ordinary share for every three allocated in the placing, subscription or retail offer with an exercise price of 0.9p/share at any time in the two years following the date of grant. all directors participated in the placing for a total value of £80,000. already servicing 85% of target top 20 global pharma companies, the new funding will be used by the group to gain reputation as the ‘go-to’ platform for the development of therapeutics for specific target classes within the ‘dark proteome’, deliver best-in-class ai/ml models capable of securing premium collaborative partnerships, leverage the existing £10m automation laboratory that powers its optimer® discovery engine and accelerate the unlocking of licensing deals for new therapies through generation of in vivo data. delivering such a strategy can be expected to provide a clear pathway to value realisation, through the collection of fee-for-service (‘ffs’) payments plus collaborative partnerships as therapeutic assets advance, leading to milestones and royalty streams, therein creating a credible path to a nasdaq listing and/or credible m&a approaches. on 18 february 2026, tpi placed a fair value of £140m on aptamer, suggesting a target price of 6p/share.
risk warning: potential valuations and price targets are based on financial modelling and there is no guarantee that such valuations, financial forecasts or price targets will ever be reali
Sign In
Follow the stocks
